Pallas Capital Advisors LLC Biocryst Pharmaceuticals Inc Transaction History
Pallas Capital Advisors LLC
- $2.43 Billion
- Q2 2025
A detailed history of Pallas Capital Advisors LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 14,079 shares of BCRX stock, worth $127,555. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,079
Previous 19,797
28.88%
Holding current value
$127,555
Previous $155,000
18.71%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
295Shares Held
181MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$196 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$181 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$80.9 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$78.8 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$70.8 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.68B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...